Publication: Strategies for the use of Ginkgo biloba extract, EGb 761<sup>®</sup>, in the treatment and management of mild cognitive impairment in Asia: Expert consensus
Issued Date
2021-02-01
Resource Type
ISSN
17555949
17555930
17555930
Other identifier(s)
2-s2.0-85097874280
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
CNS Neuroscience and Therapeutics. Vol.27, No.2 (2021), 149-162
Suggested Citation
Nagaendran Kandiah, Yee Fai Chan, Christopher Chen, Darwin Dasig, Jacqueline Dominguez, Seol Heui Han, Jianping Jia, Sang Yun Kim, Panita Limpawattana, Li Ling Ng, Dinh Toan Nguyen, Paulus Anam Ong, Encarnita Raya-Ampil, Nor'izzati Saedon, Vorapun Senanarong, Siti Setiati, Harjot Singh, Chuthamanee Suthisisang, Tong Mai Trang, Yuda Turana, Narayanaswamy Venketasubramanian, Fee Mann Yong, Yong Chul Youn, Ralf Ihl Strategies for the use of Ginkgo biloba extract, EGb 761<sup>®</sup>, in the treatment and management of mild cognitive impairment in Asia: Expert consensus. CNS Neuroscience and Therapeutics. Vol.27, No.2 (2021), 149-162. doi:10.1111/cns.13536 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78491
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Strategies for the use of Ginkgo biloba extract, EGb 761<sup>®</sup>, in the treatment and management of mild cognitive impairment in Asia: Expert consensus
Author(s)
Nagaendran Kandiah
Yee Fai Chan
Christopher Chen
Darwin Dasig
Jacqueline Dominguez
Seol Heui Han
Jianping Jia
Sang Yun Kim
Panita Limpawattana
Li Ling Ng
Dinh Toan Nguyen
Paulus Anam Ong
Encarnita Raya-Ampil
Nor'izzati Saedon
Vorapun Senanarong
Siti Setiati
Harjot Singh
Chuthamanee Suthisisang
Tong Mai Trang
Yuda Turana
Narayanaswamy Venketasubramanian
Fee Mann Yong
Yong Chul Youn
Ralf Ihl
Yee Fai Chan
Christopher Chen
Darwin Dasig
Jacqueline Dominguez
Seol Heui Han
Jianping Jia
Sang Yun Kim
Panita Limpawattana
Li Ling Ng
Dinh Toan Nguyen
Paulus Anam Ong
Encarnita Raya-Ampil
Nor'izzati Saedon
Vorapun Senanarong
Siti Setiati
Harjot Singh
Chuthamanee Suthisisang
Tong Mai Trang
Yuda Turana
Narayanaswamy Venketasubramanian
Fee Mann Yong
Yong Chul Youn
Ralf Ihl
Other Contributor(s)
Chung-Ang University Hospital
Siriraj Hospital
University Medicine and Pharmacy, Hue University
Konkuk University Medical Center
Raffles Hospital, Singapore
Xuanwu Hospital, Capital Medical University
Subang Jaya Medical Centre
Makati Medical Center
University of Santo Tomas, Manila
St. Luke's Medical Center Quezon City
Universitas Katolik Indonesia Atma Jaya
Universitas Padjadjaran
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
Alexianer Krefeld GmbH
Universiti Malaya
NUS Yong Loo Lin School of Medicine
Faculty of Medicine, Khon Kaen University
Kuala Lumpur Hospital
National Neuroscience Institute of Singapore
Changi General Hospital
Mahidol University
Seoul National University College of Medicine
Duke-NUS
Dr Harjot Singh's Neuropsychiatry Centre and Hospital
University Medical Center
Lee Kong Chian School of Business
Siriraj Hospital
University Medicine and Pharmacy, Hue University
Konkuk University Medical Center
Raffles Hospital, Singapore
Xuanwu Hospital, Capital Medical University
Subang Jaya Medical Centre
Makati Medical Center
University of Santo Tomas, Manila
St. Luke's Medical Center Quezon City
Universitas Katolik Indonesia Atma Jaya
Universitas Padjadjaran
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
Alexianer Krefeld GmbH
Universiti Malaya
NUS Yong Loo Lin School of Medicine
Faculty of Medicine, Khon Kaen University
Kuala Lumpur Hospital
National Neuroscience Institute of Singapore
Changi General Hospital
Mahidol University
Seoul National University College of Medicine
Duke-NUS
Dr Harjot Singh's Neuropsychiatry Centre and Hospital
University Medical Center
Lee Kong Chian School of Business
Abstract
Background: Mild cognitive impairment (MCI) is a neurocognitive state between normal cognitive aging and dementia, with evidence of neuropsychological changes but insufficient functional decline to warrant a diagnosis of dementia. Individuals with MCI are at increased risk for progression to dementia; and an appreciable proportion display neuropsychiatric symptoms (NPS), also a known risk factor for dementia. Cerebrovascular disease (CVD) is thought to be an underdiagnosed contributor to MCI/dementia. The Ginkgo biloba extract, EGb 761®, is increasingly being used for the symptomatic treatment of cognitive disorders with/without CVD, due to its known neuroprotective effects and cerebrovascular benefits. Aims: To present consensus opinion from the ASian Clinical Expert group on Neurocognitive Disorders (ASCEND) regarding the role of EGb 761® in MCI. Materials & Methods: The ASCEND Group reconvened in September 2019 to present and critically assess the current evidence on the general management of MCI, including the efficacy and safety of EGb 761® as a treatment option. Results: EGb 761® has demonstrated symptomatic improvement in at least four randomized trials, in terms of cognitive performance, memory, recall and recognition, attention and concentration, anxiety, and NPS. There is also evidence that EGb 761® may help delay progression from MCI to dementia in some individuals. Discussion: EGb 761® is currently recommended in multiple guidelines for the symptomatic treatment of MCI. Due to its beneficial effects on cerebrovascular blood flow, it is reasonable to expect that EGb 761® may benefit MCI patients with underlying CVD. Conclusion: As an expert group, we suggest it is clinically appropriate to incorporate EGb 761® as part of the multidomain intervention for MCI.
